JPH0465982B2 - - Google Patents

Info

Publication number
JPH0465982B2
JPH0465982B2 JP59095655A JP9565584A JPH0465982B2 JP H0465982 B2 JPH0465982 B2 JP H0465982B2 JP 59095655 A JP59095655 A JP 59095655A JP 9565584 A JP9565584 A JP 9565584A JP H0465982 B2 JPH0465982 B2 JP H0465982B2
Authority
JP
Japan
Prior art keywords
particles
reaction
liquid
agglutination reaction
agglutination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP59095655A
Other languages
Japanese (ja)
Other versions
JPS60239670A (en
Inventor
Hiroyoshi Kashiwade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Rebio Kk
Original Assignee
Fuji Rebio Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Rebio Kk filed Critical Fuji Rebio Kk
Priority to JP59095655A priority Critical patent/JPS60239670A/en
Publication of JPS60239670A publication Critical patent/JPS60239670A/en
Publication of JPH0465982B2 publication Critical patent/JPH0465982B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30Micromixers

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

〔発明の目的〕 (産業上の利用分野) 凝集反応を利用した検査方法は、血液型の判定
に用いられているが、最近は動物赤血球その他の
担体粒子に種々の抗原あるいは抗体等を感作する
ことにより各種ウイルス感染症の検査さらには抗
体あるいは抗原等の生理活性物質の測定に広く利
用されるようになつてきている。本発明は、こ
の、免疫化学分野、生物化学分野など、とりわげ
臨床検査分野で多用されている、この凝集反応を
利用した分析方法を改良するものである。 (従来の技術) 従来の凝集反応には、血液型の判定などで利用
されている、粒子自ら具有している抗原等を利用
した直接凝集反応と、抗原等を担体粒子に感作さ
せてこの感作粒子を凝集させる間接凝集反応とが
あるが、いずれの方法においても凝集反応はマイ
クロプレートのウエルあるいは小試験管内などで
行なわれていた。この凝集反応を利用した分析法
では一番微量で測定できるマイクロプレート法で
も反応液量を50〜125μ程度要していた。これ
により極微量の場合には、例えば血液型の判定に
は溶血反応などが利用されていた。 (発明が解決しようとする問題点) 溶血反応法は操作に5段階を要するなど煩雑で
あり、かつ分析対象が限定され、一方凝集反応法
の場合には微量とはいえ相当量の試料及び試薬を
必要とするところから、極微量しか試料を入手で
きない場合にはこの方法を利用できなかつた。 〔発明の構成〕 本発明は、凝集反応を流動パラフイン等の液体
内に水滴を導入してこの水滴内で凝集反応させる
ことによつて極微量で分析しうるようにしたとこ
ろに特徴があり、この特定の液体を振盪しあるい
は遠心するなどしても水滴が分散などせず、凝集
反応の場として充分利用できることを見出してな
されたものである。 (問題点を解決するための手段) 本発明は、凝集反応を利用した免疫化学的分析
方法において、透明であり、水に不溶性であり、
当該凝集反応に不活性であり、比重が1〜0.7で
あり、かつ不揮発性の液体の内部に、少なくとも
分析対象生理活性物質の存在に応じて凝集反応す
る粒子と検体とが共存する水溶液の場を形成し、
当該場における当該粒子の凝集状態を検査するこ
とを特徴とする生理活性物質の分析方法に関する
ものである。 水溶液の場を形成させる液体は、透明であるこ
と、水に不溶性であること、当該凝集反応に不活
性であること、比重が1〜0.7程度あること、及
び不揮発性であることが少なくとも必要である。
すなわち、この液体は凝集状態を検査するために
透明でなければならず、水溶液の場を形成させる
ために水に不溶性でなければならない。また、非
特異反応を防止するために当該凝集反応に不活性
でなければならず、液体内部に水溶液の場を形成
させるために比重が1〜0.7でなければならない。
さらに、この液体は凝集反応を終了して検査に至
るまで存在していなければならないから不揮発性
でなければならない。この液体の比重は特に0.85
〜1程度が好ましい。この液体はさらに低粘度で
あることが好ましい。このような液体の例として
流動パラフイン及びこのような条件を満たすシリ
コンオイルなどを挙げることができる。これらの
なかで特に流動パラフインが本発明の方法に好適
である。 液体を入れる容器は特に限定されないが、テラ
サキプレートあるいはマイクロプレートのウエル
などを利用することができる。各ウエルに入れる
液量は一定でなくともよいが、例えばテラサキプ
レートの場合には1ウエルあたり5〜10μ程度
を入れればよい。 このような液体の内部に形成される場の水溶液
は通常の凝集反応と同様でよく、凝集反応の種類
に応じて定められる。本発明の方法を適用しうる
凝集反応の種類は特に制限されるものではなく、
血液型の判定などに利用されている直接凝集反応
のほか、梅毒トレポネーマ・パリダム、ストレプ
トリジンO、ストレプトキナーゼ、マイコプラズ
マ、トキソプラズマなどの各種感染症による抗体
の検出、サイログロブリン、エリテマトーデス、
リユーマチフアクターなどを各種自己免疫性抗体
の検出、HBSなどのウエルス関連抗原の検出、
HGG、HPLなどのペプタイドホルモンの検出、
AFP、フエリチン、β2−マイクログロブリンな
どの癌関連抗原の検出などに広く利用できる。 これらの分析対象生理活性物質の存在に応じて
凝集反応する粒子は凝集反応に通常使用される感
作粒子等をそのまま用いればよく、例えば、抗
原、抗体等を感作したゼラチン粒子(特開昭57−
153658号公報など)、ポリスチレンラテツクス、
ベントナイト、カオリン、炭末、動物赤血球、細
菌などを利用できる。粒径は小さいほうが好まし
く、1〜3μm程度が特に好ましい。これよりも
粒径の大きなものを使用する場合には非特異反応
を防止するために粒子の濃度を通常の凝集反応の
場合よりも低くすることが好ましい。非特異反応
がほとんどなく、また、1〜3μm程度の微粒子
が容易に得られること、さらに着色が容易であり
凝集状態を判別しやすいことなどの点からゼラチ
ン粒子が特に好ましい。 水溶液の場は0.5〜10μ、特に2〜3μ程度の
水溶液を用いて水滴状態に形成する。この水滴
は、例えば粒子の懸濁液、検体、その他必要な液
をマイクロシリンジに所定量づつ吸引して、この
各液を最初の液滴内に次々と注入することにより
一つの液滴を形成させるようにすればよい。 注入後は振盪等により水溶液内を混合し、所定
時間放置後、凝集状態を検査すればよい。 検査は、光学顕微鏡等を利用して肉眼で観察し
てもよく、オートアナライザー等を用いて自動化
することもできる。 (作用) 水溶液の量が数μの場合には机上では瞬時に
蒸発してしまうが、流動パラフイン等の液体に包
囲させることによつてこの蒸発を防止している。
また、この液体は水溶液の液滴を分散させずに安
定して存在させるという機能も果たしている。 〔発明の効果〕 数μという極微量の水溶液内で凝集反応させ
ることができ、その結果、検体量も試薬量も極微
量で足りるようになつた。溶血反応を利用した方
法に比し、凝集反応法は操作が格段に簡単である
ところから、この極微量分析は簡便に行なえるよ
うになつた。また、間接凝集反応法においても直
接凝集反応法のような凝集塊が形成されるところ
から判断をより容易に行なえるようになつた。 〔実施例〕 血清リンパ球及び脳抽出物についてリンパ球の
型判定を行なつた。 各種血清検体をフイコール・コンレイ比重遠心
法で分離してリンパ球を集め28kHzの超音波で5
分間処理した。この超音波処理したリンパ球及び
別途調製した脳抽出物をいずれも粒径1〜3.2μm
の赤色に着色されたゼラチン粒子(富士レビオ株
式会社製)又は粒径0.5μmのポリスチレンラテツ
クス粒子(武田薬品工業(株))製)に感作した。感
作方法としては、ゼラチン粒子の場合には2ppm
のタンニン酸溶液を利用して行ない、ポリスチレ
ンラテツクス粒子の場合には0.2Mグリシン緩衝
液PH8.2に0.25%濃度に浮遊させ、いずれも常法
により感作を行なつた。 比重0.875の流動パラフインをテラサキプレー
トの各ウエルに約5μ宛入れ、これに抗血清1μ
及び上記の0.125%感作粒子浮遊液1μを一つ
の液滴を形成するようにマイクロシリンジで注入
した。これをマイクロミキサーで5分間撹拌後室
温で30分間放置し、各ウエルの凝集状態を40〜
100倍の光学顕微鏡で検鏡して調べ、型判定を行
なつた。 得られた結果を下表に示す。
[Purpose of the invention] (Field of industrial application) Testing methods using agglutination reactions are used to determine blood types, but recently animal red blood cells and other carrier particles are sensitized to various antigens or antibodies. As a result, it has become widely used for testing various viral infections and for measuring physiologically active substances such as antibodies and antigens. The present invention aims to improve the analytical method using this agglutination reaction, which is frequently used in the field of immunochemistry, biochemistry, etc., and especially in the field of clinical testing. (Prior art) Conventional agglutination reactions include direct agglutination reactions that utilize antigens contained in the particles themselves, which are used in blood type determination, and sensitized carrier particles with antigens. There is an indirect agglutination reaction in which sensitized particles are agglomerated, but in either method, the agglutination reaction is carried out in the wells of a microplate or in a small test tube. In the analytical method using this agglutination reaction, even the microplate method, which allows measurement in the smallest amount, requires a reaction solution volume of about 50 to 125 microns. As a result, in the case of extremely small amounts, hemolytic reactions have been used, for example, to determine blood type. (Problems to be Solved by the Invention) The hemolytic reaction method is complicated, requiring five steps, and the analysis target is limited, while the agglutination reaction method requires a considerable amount of sample and reagent, albeit a small amount. This method cannot be used when only a trace amount of sample is available. [Structure of the Invention] The present invention is characterized in that the aggregation reaction can be analyzed in extremely small amounts by introducing water droplets into a liquid such as liquid paraffin and causing the aggregation reaction within the water droplets. This was done based on the discovery that even if this particular liquid was shaken or centrifuged, the water droplets would not disperse and could be fully used as a site for aggregation reactions. (Means for Solving the Problems) The present invention provides an immunochemical analysis method using an agglutination reaction, which is transparent and insoluble in water.
An aqueous solution where particles and a specimen coexist, which are inert to the agglutination reaction, have a specific gravity of 1 to 0.7, and are nonvolatile, at least in response to the presence of the physiologically active substance to be analyzed. form,
The present invention relates to a method for analyzing a physiologically active substance, which is characterized by inspecting the agglomeration state of the particles in the field. The liquid that forms the aqueous solution field must at least be transparent, insoluble in water, inert to the aggregation reaction, have a specific gravity of about 1 to 0.7, and be nonvolatile. be.
That is, the liquid must be transparent in order to examine the state of agglomeration, and it must be insoluble in water to allow the formation of aqueous fields. Furthermore, it must be inert to the aggregation reaction to prevent non-specific reactions, and must have a specific gravity of 1 to 0.7 to form an aqueous field within the liquid.
Furthermore, this liquid must be nonvolatile because it must exist until the agglutination reaction is completed and the test is carried out. The specific gravity of this liquid is especially 0.85
~1 is preferable. Preferably, this liquid also has a low viscosity. Examples of such liquids include liquid paraffin and silicone oil that satisfies these conditions. Among these, liquid paraffin is particularly suitable for the method of the present invention. The container for containing the liquid is not particularly limited, but a Terasaki plate or a well of a microplate can be used. Although the amount of liquid added to each well does not have to be constant, for example, in the case of a Terasaki plate, about 5 to 10 microns may be added per well. The field aqueous solution formed inside such a liquid may be the same as in a normal flocculation reaction, and is determined depending on the type of flocculation reaction. The type of aggregation reaction to which the method of the present invention can be applied is not particularly limited,
In addition to the direct agglutination reaction used to determine blood type, detection of antibodies caused by various infectious diseases such as Treponema pallidum, streptolysin O, streptokinase, mycoplasma, toxoplasma, thyroglobulin, lupus erythematosus,
Detection of various autoimmune antibodies such as rheumatism factor, detection of virus-related antigens such as HBS ,
Detection of peptide hormones such as HGG and HPL,
It can be widely used to detect cancer-related antigens such as AFP, ferritin, and β 2 -microglobulin. The particles that undergo an agglutination reaction in response to the presence of the physiologically active substance to be analyzed may be sensitized particles that are normally used for agglutination reactions. For example, gelatin particles sensitized with antigens, antibodies, etc. 57−
153658), polystyrene latex,
Bentonite, kaolin, charcoal powder, animal red blood cells, bacteria, etc. can be used. The smaller the particle size is, the more preferable it is, and particularly preferably about 1 to 3 μm. When using particles with a larger diameter than this, it is preferable to lower the particle concentration than in the case of a normal agglutination reaction in order to prevent non-specific reactions. Gelatin particles are particularly preferred because there is almost no non-specific reaction, fine particles of about 1 to 3 μm can be easily obtained, and furthermore, they are easily colored and the state of aggregation can be easily determined. The aqueous solution field is formed into a water droplet using an aqueous solution having a diameter of 0.5 to 10 μm, particularly 2 to 3 μm. This water droplet is formed by, for example, aspirating a predetermined amount of a particle suspension, a sample, or any other necessary liquid into a microsyringe, and injecting each liquid one after another into the first droplet. All you have to do is let it happen. After injection, the aqueous solution may be mixed by shaking or the like, and after being left for a predetermined period of time, the state of aggregation may be inspected. The inspection may be observed with the naked eye using an optical microscope or the like, or may be automated using an autoanalyzer or the like. (Function) When the amount of aqueous solution is several μ, it evaporates instantly on paper, but this evaporation is prevented by surrounding it with liquid such as liquid paraffin.
Moreover, this liquid also fulfills the function of allowing the droplets of the aqueous solution to exist stably without being dispersed. [Effects of the Invention] The agglutination reaction can be carried out in an extremely small amount of aqueous solution of several μm, and as a result, only extremely small amounts of specimen and reagent are required. Since the agglutination reaction method is much easier to operate than methods using hemolysis reactions, this ultra-trace analysis has become easy to perform. In addition, even in the indirect agglutination reaction method, it has become easier to judge based on the formation of aggregates as in the direct agglutination reaction method. [Example] Lymphocyte typing was performed on serum lymphocytes and brain extracts. Separate various serum samples using Ficoll-Conray specific gravity centrifugation and collect lymphocytes using 28kHz ultrasound.
Processed for minutes. Both the ultrasonicated lymphocytes and the separately prepared brain extract had a particle size of 1 to 3.2 μm.
The cells were sensitized to red-colored gelatin particles (manufactured by Fujirebio Co., Ltd.) or polystyrene latex particles (manufactured by Takeda Pharmaceutical Co., Ltd.) with a particle size of 0.5 μm. The sensitization method is 2ppm for gelatin particles.
In the case of polystyrene latex particles, they were suspended in a 0.2M glycine buffer pH 8.2 at a concentration of 0.25%, and sensitization was carried out using a conventional method. Add about 5μ of liquid paraffin with a specific gravity of 0.875 to each well of the Terasaki plate, and add 1μ of antiserum to this.
And 1μ of the above 0.125% sensitized particle suspension was injected with a microsyringe so as to form one droplet. After stirring this for 5 minutes with a micro mixer, it was left at room temperature for 30 minutes, and the aggregation state of each well was adjusted to 40 to 40 minutes.
They examined it using a 100x optical microscope and determined the type. The results obtained are shown in the table below.

【表】 尚、従来の溶血反応法の測定結果はゼラチン粒
子の場合と完全に一致した。
[Table] The measurement results obtained using the conventional hemolytic reaction method were completely consistent with those obtained using gelatin particles.

Claims (1)

【特許請求の範囲】[Claims] 1 凝集反応を利用した免疫化学的分析方法にお
いて、透明であり、水に不溶性であり、当該凝集
反応に不溶性であり、比重が1〜0.7であり、か
つ不揮発性の液体の内部に、少なくとも分析対象
生理活性物質の存在に応じて凝集反応する粒子と
検体とが共存する水溶液の場を形成し、当該場に
おける当該粒子の凝集状態を検査することを特徴
とする生理活性物質の分析方法。
1. In an immunochemical analysis method using an agglutination reaction, at least the analytical substance is transparent, insoluble in water, insoluble in the agglutination reaction, has a specific gravity of 1 to 0.7, and is nonvolatile. A method for analyzing a physiologically active substance, which comprises forming an aqueous field where particles and a specimen coexist in an aggregation reaction depending on the presence of the target physiologically active substance, and inspecting the aggregation state of the particles in the field.
JP59095655A 1984-05-15 1984-05-15 Immunochemical analysis utilizing agglutination reaction Granted JPS60239670A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59095655A JPS60239670A (en) 1984-05-15 1984-05-15 Immunochemical analysis utilizing agglutination reaction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59095655A JPS60239670A (en) 1984-05-15 1984-05-15 Immunochemical analysis utilizing agglutination reaction

Publications (2)

Publication Number Publication Date
JPS60239670A JPS60239670A (en) 1985-11-28
JPH0465982B2 true JPH0465982B2 (en) 1992-10-21

Family

ID=14143510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59095655A Granted JPS60239670A (en) 1984-05-15 1984-05-15 Immunochemical analysis utilizing agglutination reaction

Country Status (1)

Country Link
JP (1) JPS60239670A (en)

Also Published As

Publication number Publication date
JPS60239670A (en) 1985-11-28

Similar Documents

Publication Publication Date Title
CN1061142C (en) Light scatter-based immunoassay without particle self aggregation
US5858648A (en) Assays using reference microparticles
US5279936A (en) Method of separation employing magnetic particles and second medium
EP0595641B1 (en) One-step simultaneous immunoassay
US5145784A (en) Double capture assay method employing a capillary flow device
US4619904A (en) Agglutinating immunoassay using protein-coated liquid droplets
US5919419A (en) Analyzer cuvette, method and diagnostic test kit for determination of analytes in whole blood samples
US4311690A (en) Test set and method for the determination of free hormones
JPH102900A (en) Method for detecting analyte in sample liquid, reagent kit and reaction vessel
DE19856703C2 (en) Methods for the detection of antibodies or antigens
JPH05504828A (en) Capillary flow device and dual capture assay method
US20070000311A1 (en) Method for measuring substance having affinity
JPH0465982B2 (en)
US4792527A (en) Method of assaying biologically active substances and labelling agents therefor
CA2624229A1 (en) Method of assaying substance with affinity in sample containing blood-cell ingredient
GB2239197A (en) Separating a material of interest from a mixture
US10509028B2 (en) Use of a low-density immiscible compound in a device for detecting an analyte in a sample
JP3302099B2 (en) Fecal occult blood determination device
JPH0468588B2 (en)
US5288610A (en) Detecting reagent for antiplatelet antibody
JPH0875746A (en) Evaluation of agglomeration characteristics of carrier particles for immunological agglomeration reaction
JPS6262291B2 (en)
US8637270B2 (en) Fluidized bed detector for continuous, ultra-sensitive detection of biological and chemical materials
SE445680B (en) IMMUNO ANALYSIS PROCEDURE AND DEVICE FOR DETERMINATION OF BONDED SUBSTANCES
CN116047054A (en) Kit for detecting platelet antibody and preparation method and application method thereof